Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

SAN ANTONIO, and SAN FRANCISCO, Dec. 12, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.  The randomized Simon two-stage study presented at SABCS evaluated two 145 mg/m2 dose schedules of single-agent NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients who failed a prior taxane therapy.  Eighty-seven percent (61/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.

More than one million women worldwide are diagnosed with breast cancer every year and anywhere from 30% to 80% develop metastatic disease.(1)  

A total of 66 of the 70 patients treated in the Phase 2 study were assessable for the primary endpoint of objective tumor response rate (ORR),  including confirmed complete and partial responses per RECIST.  As of October 26, 2010, confirmed ORR for all evaluable patients was 32% (10/31) for the q14d schedule and 26% (9/35) for the q21d schedule, including two confirmed complete responses (CRs) on the q14d schedule.  An additional four patients had near CRs, with 100% disappearance of all target lesions.  The combined ORR for all evaluable patients was 29% (19/66).  Clinical benefit rate for the 66 evaluable patients was 41% (defined as CR+PR+SD greater than or equal to 6 mos).

"These are important new results for NKTR-102 in patients with metastatic breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... NEW YORK, Jan. 25, 2011 Reportlinker.com ... is available in its catalogue: ... analysis of small molecule brand erosion post-patent ... IntroductionPharma is facing slowing ...
... 2011 Prolong Pharmaceuticals, which in October secured a ... today announced the signing of a long term lease ... and the formal addition of Dr. Hemant Misra to ... and Facilities Operations. The manufacturing facility ...
Cached Medicine Technology:Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team 2
(Date:7/12/2014)... As reported in this July 1st article ... the June 25th, 2014 Supreme Court ruling in Riley v ... It was also met with both cheers and jeers when ... seen from an individual privacy perspective, or a law enforcement ... now precedent which will require law enforcement officials to obtain ...
(Date:7/12/2014)... July 12, 2014 Praeclarus Press ... Simple as a valuable new resource for women in ... of American women work away from their children. Today’s ... the benefits of breastfeeding, but often feel unsupported when ... their babies. With its evidence-based insights, and written by ...
(Date:7/12/2014)... Palm Beach, FL (PRWEB) July 12, 2014 ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... 2014 Recently, DressyQuinceanera.com, a well-known wedding ... Dama dresses to its online category. Furthermore, the ... at deeply discounted rates, up to 62% off. , ... equally excellent in terms of quality and style. All ... discounts are also offered for the company’s other items: ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 As ... filed against Johnson & Johnson’s Ethicon Inc. unit ... LLP notes that the Texas Attorney General’s Office ... marketing of surgical mesh products used to treat ... to a report from kens5.com, the probe began ...
Breaking Medicine News(10 mins):Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, ... temporarily zaps away forehead wrinkles by freezing the nerves ... The technique, if eventually approved by the U.S. Food ... and Dysport. Both are injectable forms of Botulinum toxin ...
... April 2011: Exciting new data presented today at the ... chronic hepatitis C (HCV) patients suppressed the emergence of ... sustained virological response - undetectable HCV RNA - 12 ... study, HCV patients were given four drugs in combination; ...
... on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer ... and presented updated results at the AACR 102nd Annual ... Heymach, M.D., Ph.D., associate professor of thoracic, head and neck ... Center, said this update details the "discovery phase" of the ...
... April 1 (HealthDay News) -- It,s important to keep injury ... Dr. Steven Greer, of the MCGHealth Sports Medicine Center in ... children. All children should undergo a physical examination before ... an extended period of time, they should begin increasing ...
... April 1 (HealthDay News) -- Updated guidelines to keep children ... released this week by the American Academy of Pediatrics. ... interests, skills and overall well-being, to ensure their child can ... to medically and mentally prepare their child for camp, and ...
... scientific discoveries in children,s health will be presented in Denver ... the Pediatric Academic Societies (PAS). This year,s gathering is a ... and more than 6,500 leaders in academic pediatrics from around ... Colorado Convention Center. Journalists will have access to ...
Cached Medicine News:Health News:Freezing Wrinkles a Possible Alternative to Botox 2Health News:Freezing Wrinkles a Possible Alternative to Botox 3Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:BATTLE researchers identify new biomarkers for EGFR inhibition 2Health News:Tips for Keeping Young Athletes Safe 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2Health News:Children's health is focus of annual meeting of Pediatric Academic Societies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: